The DOI matches its Crossref record; 291 of the 291 references it cites were found in a registry or an index.
Molecular targeting therapies for neuroblastoma: Progress and challenges
Open accessAbstract
There is an urgent need to identify novel therapies for childhood cancers. Neuroblastoma is the most common pediatric solid tumor, and accounts for ~15% of childhood cancer‐related mortality. Neuroblastomas exhibit genetic, morphological and clinical heterogeneity, which limits the efficacy of existing treatment modalities. Gaining detailed knowledge of the molecular signatures and genetic variations involved in the pathogenesis of neuroblastoma is necessary to develop safer and more effective treatments for this devastating disease. Recent studies with advanced high‐throughput “omics” techniques have revealed numerous genetic/genomic alterations and dysfunctional pathways that drive the onset, growth, progression, and resistance of neuroblastoma to therapy. A variety of molecular signatures are being evaluated to better understand the disease, with many of them being used as targets to develop new treatments for neuroblastoma patients. In this review, we have summarized the contemporary understanding of the molecular pathways and genetic aberrations, such as those in MYCN, BIRC5, PHOX2B, and LIN28B, involved in the pathogenesis of neuroblastoma, and provide a comprehensive overview of the molecular targeted therapies under preclinical and clinical investigations, particularly those targeting ALK signaling, MDM2, PI3K/Akt/mTOR and RAS‐MAPK pathways, as well as epigenetic regulators. We also give insights on the use of combination therapies involving novel agents that target various pathways. Further, we discuss the future directions that would help identify novel targets and therapeutics and improve the currently available therapies, enhancing the treatment outcomes and survival of patients with neuroblastoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: ING5‐mediated antineuroblastoma effects of suberoylanilide hydroxamic acid
Wu, J., Jiang, H., Yang, X., & Zheng, H. (2018) · Cancer Medicine · doi:10.1002/cam4.1634 · Cited by 14
RetractedThe biology , function , and biomedical applications of exosomes
Kalluri, R., & LeBleu, V. S. (2020) · Science · doi:10.1126/science.aau6977 · Cited by 10,770
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738 · cited 1×
“This has been involved in increased activation of the PI3K/Akt/mTOR pathway.(84) Further, various growth factors have been found to affect the PI3K/ Akt/mTOR pathways in NB.”
BackgroundRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
Ambrosini, G., Adida, C., & Altieri, D. C. (1997) · Nature Medicine · doi:10.1038/nm0897-917 · Cited by 3,165
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Neuroblastoma: biological insights into a clinical enigma
Brodeur, G. M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1014 · Cited by 2,160
Necroptosis and its role in inflammation
Pasparakis, M., & Vandenabeele, P. (2015) · Nature · doi:10.1038/nature14191 · Cited by 2,148
Association of Multiple Copies of the N-myc Oncogene with Rapid Progression of Neuroblastomas
Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., & Hammond, D. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510313131802 · Cited by 2,010
Recent Advances in Neuroblastoma
Maris, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0804577 · Cited by 1,983
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
Cohn, S. L., Pearson, A. D. J., London, W. B., Monclair, T., Ambros, P. F., Brodeur, G. M., Faldum, A., Hero, B., Iehara, T., Machin, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6785 · Cited by 1,910
The biology and function of exosomes in cancer
Kalluri, R. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81135 · Cited by 1,849
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835
VEGF as a Key Mediator of Angiogenesis in Cancer
Carmeliet, P. (2005) · Oncology · doi:10.1159/000088478 · Cited by 1,768
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712
Tischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarowicz, D., Fiddes, J. C., & Abraham, J. A. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99049-6 · Cited by 1,476
Matthay, K. K., Maris, J. M., Schleiermacher, G., Nakagawara, A., Mackall, C. L., Diller, L., & Weiss, W. A. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.78 · Cited by 1,419
Identification of ALK as a major familial neuroblastoma predisposition gene
Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, P., et al. (2008) · Nature · doi:10.1038/nature07261 · Cited by 1,407
Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance
Mashouri, L., Yousefi, H., Aref, A. R., Ahadi, A. M., Molaei, F., & Alahari, S. K. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0991-5 · Cited by 1,363
Goel, H. L., & Mercurio, A. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3627 · Cited by 1,253
The genetic landscape of high-risk neuroblastoma
Pugh, T. J., Morozova, O., Attiyeh, E. F., Asgharzadeh, S., Wei, J. S., Auclair, D., Carter, S. L., Cibulskis, K., Hanna, M., Kiezun, A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2529 · Cited by 1,186
Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5—a population-based study
Gatta, G., Botta, L., Rossi, S., Aareleid, T., Bielska-Lasota, M., Clavel, J., Dimitrova, N., Jakab, Z., Kaatsch, P., Lacour, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70548-5 · Cited by 1,075
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
Ferrara, N., Hillan, K. J., & Novotny, W. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.132 · Cited by 977
Tamkun, J. W., Deuring, R., Scott, M. P., Kissinger, M., Pattatucci, A. M., Kaufman, T. C., & Kennison, J. A. (1992) · Cell · doi:10.1016/0092-8674(92)90191-e · Cited by 971
Oncogenic mutations of ALK kinase in neuroblastoma
Chen, Y., Takita, J., Choi, Y. L., Kato, M., Ohira, M., Sanada, M., Wang, L., Soda, M., Kikuchi, A., Igarashi, T., et al. (2008) · Nature · doi:10.1038/nature07399 · Cited by 916
Advances in Risk Classification and Treatment Strategies for Neuroblastoma
Pinto, N. R., Applebaum, M. A., Volchenboum, S. L., Matthay, K. K., London, W. B., Ambros, P. F., Nakagawara, A., Berthold, F., Schleiermacher, G., Park, J. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4648 · Cited by 911
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Janoueix-Lerosey, I., Lequin, D., Brugières, L., Ribeiro, A., de Pontual, L., Combaret, V., Raynal, V., Puisieux, A., Schleiermacher, G., Pierron, G., et al. (2008) · Nature · doi:10.1038/nature07398 · Cited by 894
Activating mutations in ALK provide a therapeutic target in neuroblastoma
George, R. E., Sanda, T., Hanna, M., Fröhling, S., II, W. L., Zhang, J., Ahn, Y., Zhou, W., London, W. B., McGrady, P., et al. (2008) · Nature · doi:10.1038/nature07397 · Cited by 893
Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brain
Dovey, H. F., John, V., Anderson, J. P., Chen, L. Z., De Saint Andrieu, P., Fang, L. Y., Freedman, S. B., Folmer, B., Goldbach, E., Holsztynska, E. J., et al. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00012.x · Cited by 875
Shimada, H., Chatten, J., Newton, W. A., Sachs, N., Hamoudi, A. B., Chiba, T., Marsden, H. B., & Misugi, K. (1984) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/73.2.405 · Cited by 862
Matthay, K. K., Reynolds, C. P., Seeger, R. C., Shimada, H., Adkins, E. S., Haas-Kogan, D., Gerbing, R. B., London, W. B., & Villablanca, J. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8925 · Cited by 858
Moll, U. M., & Petrenko, O. (2003) · PubMed · Cited by 780
Mossé, Y. P., Lim, M. S., Voss, S. D., Wilner, K., Ruffner, K., Laliberte, J., Rolland, D., Balis, F. M., Maris, J. M., Weigel, B. J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70095-0 · Cited by 712
Nakagawara, A., Arima-Nakagawara, M., Scavarda, N. J., Azar, C. G., Cantor, A. B., & Brodeur, G. M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199303253281205 · Cited by 694
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
Puissant, A., Frumm, S. M., Alexe, G., Bassil, C. F., Qi, J., Chanthery, Y. H., Nekritz, E. A., Zeid, R., Gustafson, W. C., Greninger, P., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0418 · Cited by 637
CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
Sakamoto, H., Tsukaguchi, T., Hiroshima, S., Kodama, T., Kobayashi, T., Fukami, T. A., Oikawa, N., Tsukuda, T., Ishii, N., & Aoki, Y. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.004 · Cited by 636
Neuroblastoma: Biology, Prognosis, and Treatment
Park, J. R., Eggert, A., & Caron, H. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.11.011 · Cited by 620
Vascular endothelial growth factor (VEGF) signaling in tumor progression
Roskoski, R. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.01.006 · Cited by 599
RIP Kinase-Dependent Necrosis Drives Lethal Systemic Inflammatory Response Syndrome
Duprez, L., Takahashi, N., Van Hauwermeiren, F., Vandendriessche, B., Goossens, V., Vanden Berghe, T., Declercq, W., Libert, C., Cauwels, A., & Vandenabeele, P. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.020 · Cited by 583
Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma
Attiyeh, E. F., London, W. B., Mossé, Y. P., Wang, Q., Winter, C., Khazi, D., McGrady, P. W., Seeger, R. C., Look, A. T., Shimada, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052399 · Cited by 580
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
Eleveld, T. F., Oldridge, D. A., Bernard, V., Koster, J., Daage, L. C., Diskin, S. J., Schild, L., Bentahar, N. B., Bellini, A., Chicard, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3333 · Cited by 540
The pediatric preclinical testing program: Description of models and early testing results
Houghton, P. J., Morton, C. L., Tucker, C., Payne, D., Favours, E., Cole, C., Gorlick, R., Kolb, E. A., Zhang, W., Lock, R., et al. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21078 · Cited by 480
ATM Mutations in Cancer: Therapeutic Implications
Choi, M., Kipps, T., & Kurzrock, R. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0945 · Cited by 453
Moll, U. M., LaQuaglia, M., Bénard, J., & Riou, G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.10.4407 · Cited by 427
Expression and function of TRK-B and BDNF in human neuroblastomas.
Nakagawara, A., Azar, C. G., Scavarda, N. J., & Brodeur, G. M. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.1.759 · Cited by 423
Berthold, F., Boos, J., Burdach, S., Erttmann, R., Henze, G., Hermann, J., Klingebiel, T., Kremens, B., Schilling, F. H., Schrappe, M., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70291-6 · Cited by 402
Jögi, A., Øra, I., Nilsson, H., Lindeheim, Å., Makino, Y., Poellinger, L., Axelson, H., & Påhlman, S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.102660199 · Cited by 399
Bresler, S. C., Weiser, D. A., Huwe, P. J., Park, J. H., Krytska, K., Ryles, H., Laudenslager, M., Rappaport, E. F., Wood, A. C., McGrady, P. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.019 · Cited by 388
Islam, A., Kageyama, H., Takada, N., Kawamato, T., Takayasu, H., Isogai, E., Ohira, M., Hashizume, K., Kobayashi, H., Kaneko, Y., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203358 · Cited by 386
LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression
Molenaar, J. J., Domingo-Fernández, R., Ebus, M. E., Lindner, S., Koster, J., Drabek, K., Mestdagh, P., van Sluis, P., Valentijn, L. J., van Nes, J., et al. (2012) · Nature Genetics · doi:10.1038/ng.2436 · Cited by 383
Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis
Zhu, S., Lee, J.-S., Guo, F., Shin, J., Perez-Atayde, A. R., Kutok, J. L., Rodig, S. J., Neuberg, D. S., Helman, D., Feng, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.010 · Cited by 365
Self-citationChallagundla, K. B., Wise, P. M., Neviani, P., Chava, H., Murtadha, M., Xu, T., Kennedy, R., Ivan, C., Zhang, X., Vannini, I., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv135 · Cited by 359
Germline Mutations of the Paired–Like Homeobox 2B (PHOX2B) Gene in Neuroblastoma
Trochet, D., Bourdeaut, F., Janoueix-Lerosey, I., Deville, A., de Pontual, L., Schleiermacher, G., Coze, C., Philip, N., Frébourg, T., Munnich, A., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/383253 · Cited by 358
Park, J. R., Kreissman, S. G., London, W. B., Naranjo, A., Cohn, S. L., Hogarty, M. D., Tenney, S. C., Haas-Kogan, D., Shaw, P. J., Kraveka, J. M., et al. (2019) · JAMA · doi:10.1001/jama.2019.11642 · Cited by 358
Eggert, A., Ikegaki, N., Kwiatkowski, J. L., Zhao, H., Brodeur, G. M., & Himelstein, B. P. (2000) · PubMed · Cited by 353
A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma
Wallace, E. M., Rizzi, J. P., Han, G., Wehn, P. M., Cao, Z., Du, X., Cheng, T., Czerwinski, R. M., Dixon, D. D., Goggin, B. S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0473 · Cited by 336
The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma
Berry, T., Luther, W., Bhatnagar, N., Jamin, Y., Poon, E., Sanda, T., Pei, D., Sharma, B., Vetharoy, W. R., Hallsworth, A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.001 · Cited by 326
Self-citationNatural Killer–Derived Exosomal miR-186 Inhibits Neuroblastoma Growth and Immune Escape Mechanisms
Neviani, P., Wise, P. M., Murtadha, M., Liu, C. W., Wu, C.-H., Jong, A. Y., Seeger, R. C., & Fabbri, M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-0779 · Cited by 324
London, W. B., Castel, V., Monclair, T., Ambros, P. F., Pearson, A. D. J., Cohn, S. L., Berthold, F., Nakagawara, A., Ladenstein, R. L., Iehara, T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3392 · Cited by 318
Trk Receptor Expression and Inhibition in Neuroblastomas
Brodeur, G. M., Minturn, J. E., Ho, R., Simpson, A. M., Iyer, R., Varela, C. R., Light, J. E., Kolla, V., & Evans, A. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1815 · Cited by 307
Neuroblastoma: clinical and biological approach to risk stratification and treatment
Tolbert, V. P., & Matthay, K. K. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2821-2 · Cited by 304
Germline PHOX2B Mutation in Hereditary Neuroblastoma
Mosse, Y. P., Laudenslager, M., Khazi, D., Carlisle, A. J., Winter, C. L., Rappaport, E., & Maris, J. M. (2004) · The American Journal of Human Genetics · doi:10.1086/424530 · Cited by 284
De Brouwer, S., De Preter, K., Kumps, C., Zabrocki, P., Porcu, M., Westerhout, E. M., Lakeman, A., Vandesompele, J., Hoebeeck, J., Van Maerken, T., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2660 · Cited by 279
Updates in Diagnosis, Management, and Treatment of Neuroblastoma
Swift, C. C., Eklund, M. J., Kraveka, J. M., & Alazraki, A. L. (2018) · RadioGraphics · doi:10.1148/rg.2018170132 · Cited by 279
Mody, R., Naranjo, A., Van Ryn, C., Yu, A. L., London, W. B., Shulkin, B. L., Parisi, M. T., Servaes, S.-E.-N., Diccianni, M. B., Sondel, P. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30355-8 · Cited by 277
Neuroblastoma—A Neural Crest Derived Embryonal Malignancy
Johnsen, J. I., Dyberg, C., & Wickström, M. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00009 · Cited by 277
γ-Secretase inhibitors and modulators
Golde, T. E., Koo, E. H., Felsenstein, K. M., Osborne, B. A., & Miele, L. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.06.005 · Cited by 272
Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma
Diskin, S. J., Capasso, M., Schnepp, R. W., Cole, K. A., Attiyeh, E. F., Hou, C., Diamond, M., Carpenter, E. L., Winter, C., Lee, H., et al. (2012) · Nature Genetics · doi:10.1038/ng.2387 · Cited by 266
Rayburn, E., Zhang, R., He, J., & Wang, H. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332636 · Cited by 265
Self-citationMatthay, K. K., Yanik, G., Messina, J., Quach, A., Huberty, J., Cheng, S.-C., Veatch, J., Goldsby, R., Brophy, P., Kersun, L. S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3484 · Cited by 264
ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma
Hogarty, M. D., Norris, M. D., Davis, K., Liu, X., Evageliou, N. F., Hayes, C. S., Pawel, B., Guo, R., Zhao, H., Sekyere, E., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6866 · Cited by 262
King, D., Yeomanson, D., & Bryant, H. E. (2015) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000329 · Cited by 248 · cited 1×
“For example, the PI3/Akt/mTOR pathway contributes to MYCN stabilization, and MYCN, in turn, contributes to several processes associated with malignancy, such as proliferation, angiogenesis, and altering metabolic programming.(87,88) A study by Chesler et al.”
BackgroundMYC in Oncogenesis and as a Target for Cancer Therapies
(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)07006-5 · Cited by 242
High-Risk Neuroblastoma Treatment Review
Smith, V., & Foster, J. (2018) · Children · doi:10.3390/children5090114 · Cited by 239
Self-citationActivation of Akt Predicts Poor Outcome in Neuroblastoma
Opel, D., Poremba, C., Simon, T., Debatin, K.-M., & Fulda, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2201 · Cited by 238
Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma
Bresler, S. C., Wood, A. C., Haglund, E. A., Courtright, J., Belcastro, L. T., Plegaria, J. S., Cole, K., Toporovskaya, Y., Zhao, H., Carpenter, E. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002950 · Cited by 237
MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells
Zirath, H., Frenzel, A., Oliynyk, G., Segerström, L., Westermark, U. K., Larsson, K., Munksgaard Persson, M., Hultenby, K., Lehtiö, J., Einvik, C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222404110 · Cited by 235
Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.
Keshelava, N., Zuo, J. J., Chen, P., Waidyaratne, S. N., Luna, M. C., Gomer, C. J., Triche, T. J., & Reynolds, C. P. (2001) · PubMed · Cited by 232
Resistance to chemotherapy mediated by TrkB in neuroblastomas.
Ho, R., Eggert, A., Hishiki, T., Minturn, J. E., Ikegaki, N., Foster, P., Camoratto, A. M., Evans, A. E., & Brodeur, G. M. (2002) · PubMed · Cited by 228
Expression of the ALK Tyrosine Kinase Gene in Neuroblastoma
Lamant, L., Pulford, K., Bischof, D., Morris, S. W., Mason, D. Y., Delsol, G., & Mariamé, B. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65042-0 · Cited by 226
Matthay, K. K., DeSantes, K., Hasegawa, B., Huberty, J., Hattner, R. S., Ablin, A., Reynolds, C. P., Seeger, R. C., Weinberg, V. K., & Price, D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.229 · Cited by 222
Histone deacetylase 10 promotes autophagy-mediated cell survival
Oehme, I., Linke, J.-P., Böck, B. C., Milde, T., Lodrini, M., Hartenstein, B., Wiegand, I., Eckert, C., Roth, W., Kool, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300113110 · Cited by 221
Bosse, K. R., & Maris, J. M. (2016) · Cancer · doi:10.1002/cncr.29706 · Cited by 220
Inverse relationship between trk expression and N-myc amplification in human neuroblastomas.
Nakagawara, A., Arima, M., Azar, C. G., Scavarda, N. J., & Brodeur, G. M. (1992) · PubMed · Cited by 219
Emergence of New ALK Mutations at Relapse of Neuroblastoma
Schleiermacher, G., Javanmardi, N., Bernard, V., Leroy, Q., Cappo, J., Rio Frio, T., Pierron, G., Lapouble, E., Combaret, V., Speleman, F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0674 · Cited by 215
Anti-GD2 immunotherapy for neuroblastoma
Sait, S., & Modak, S. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1364995 · Cited by 210
Kogner, P., Barbany, G., Dominici, C., Castello, M. A., Raschellà, G., & Persson, H. (1993) · PubMed · Cited by 207
Wyce, A., Ganji, G., Smitheman, K. N., Chung, C.-W., Korenchuk, S., Bai, Y., Barbash, O., Le, B., Craggs, P. D., McCabe, M. T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072967 · Cited by 206
Chesler, L., Schlieve, C., Goldenberg, D. D., Kenney, A., Kim, G., McMillan, A., Matthay, K. K., Rowitch, D., & Weiss, W. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2769 · Cited by 202
Jaboin, J. J., Kim, C. J., Kaplan, D. R., & Thiele, C. J. (2002) · PubMed · Cited by 201
Fouladi, M., Park, J. R., Stewart, C. F., Gilbertson, R. J., Schaiquevich, P., Sun, J., Reid, J. M., Ames, M. M., Speights, R., Ingle, A. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9119 · Cited by 199
Matthay, K. K., Tan, J. C., Villablanca, J. G., Yanik, G. A., Veatch, J., Franc, B., Twomey, E., Horn, B., Reynolds, C. P., Groshen, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6400 · Cited by 197
Katzenstein, H. M., Bowman, L. C., Brodeur, G. M., Thorner, P. S., Joshi, V. V., Smith, E. I., Look, A. T., Rowe, S. T., Nash, M. B., Holbrook, T., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2007 · Cited by 190
Flahaut, M., Meier, R., Coulon, A., Nardou, K. A., Niggli, F. K., Martinet, D., Beckmann, J. S., Joseph, J.-M., Mühlethaler-Mottet, A., & Gross, N. (2009) · Oncogene · doi:10.1038/onc.2009.80 · Cited by 190
Geoerger, B., Bourdeaut, F., DuBois, S. G., Fischer, M., Geller, J. I., Gottardo, N. G., Marabelle, A., Pearson, A. D. J., Modak, S., Cash, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2898 · Cited by 190
Promising Therapeutic Targets in Neuroblastoma
Matthay, K. K., George, R. E., & Yu, A. L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1939 · Cited by 187
Neuroblastoma Origin and Therapeutic Targets for Immunotherapy
Kholodenko, I. V., Kalinovsky, D. V., Doronin, I. I., Deyev, S. M., & Kholodenko, R. V. (2018) · Journal of Immunology Research · doi:10.1155/2018/7394268 · Cited by 185
Infarinato, N. R., Park, J. H., Krytska, K., Ryles, H. T., Sano, R., Szigety, K. M., Li, Y., Zou, H. Y., Lee, N. V., Smeal, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1056 · Cited by 183
Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
Henssen, A., Althoff, K., Odersky, A., Beckers, A., Koche, R., Speleman, F., Schäfers, S., Bell, E., Nortmeyer, M., Westermann, F., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1449 · Cited by 183
Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain
Lee, C. C., Jia, Y., Li, N., Sun, X., Ng, K., Ambing, E., Gao, M.-Y., Hua, S., Chen, C., Kim, S., et al. (2010) · Biochemical Journal · doi:10.1042/bj20100609 · Cited by 182
Rettig, I., Koeneke, E., Trippel, F., Mueller, W. C., Burhenne, J., Kopp-Schneider, A., Fabian, J., Schober, A., Fernekorn, U., von Deimling, A., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.24 · Cited by 180
Eranki, A., Srinivasan, P., Ries, M., Kim, A., Lazarski, C. A., Rossi, C. T., Khokhlova, T. D., Wilson, E., Knoblach, S. M., Sharma, K. V., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1604 · Cited by 179
Newman, E. A., Abdessalam, S., Aldrink, J. H., Austin, M., Heaton, T. E., Bruny, J., Ehrlich, P., Dasgupta, R., Baertschiger, R. M., Lautz, T. B., et al. (2019) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2018.09.004 · Cited by 178
Targeting ALK in neuroblastoma—preclinical and clinical advancements
Carpenter, E. L., & Mossé, Y. P. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.72 · Cited by 177
Hagenbuchner, J., Kuznetsov, A. V., Obexer, P., & Ausserlechner, M. J. (2013) · Oncogene · doi:10.1038/onc.2012.500 · Cited by 175
Johnsen, J. I., Segerström, L., Orrego, A., Elfman, L., Henriksson, M., Kågedal, B., Eksborg, S., Sveinbjörnsson, B., & Kogner, P. (2008) · Oncogene · doi:10.1038/sj.onc.1210938 · Cited by 171
177Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma
Gains, J. E., Bomanji, J. B., Fersht, N. L., Sullivan, T., D'Souza, D., Sullivan, K. P., Aldridge, M., Waddington, W., & Gaze, M. N. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.085100 · Cited by 170
CAR T Cell Therapy for Neuroblastoma
Richards, R. M., Sotillo, E., & Majzner, R. G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02380 · Cited by 168
Origin and initiation mechanisms of neuroblastoma
Tsubota, S., & Kadomatsu, K. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2796-z · Cited by 167
Prevalence and functional consequence of PHOX2B mutations in neuroblastoma
Raabe, E. H., Laudenslager, M., Winter, C. L., Wasserman, N. F., Cole, K. A., LaQuaglia, M. P., Maris, D. J., Mossé, Y. P., & Maris, J. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210659 · Cited by 162
ALK in Neuroblastoma: Biological and Therapeutic Implications
Trigg, R. M., & Turner, S. D. (2018) · Cancers · doi:10.3390/cancers10040113 · Cited by 162
Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours
Jones, D. T. W., Banito, A., Grünewald, T. G. P., Haber, M., Jäger, N., Kool, M., Milde, T., Molenaar, J. J., Nabbi, A., Pugh, T. J., et al. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0169-x · Cited by 161
Biological Role of Anaplastic Lymphoma Kinase in Neuroblastoma
Osajima-Hakomori, Y., Miyake, I., Ohira, M., Nakagawara, A., Nakagawa, A., & Sakai, R. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62966-5 · Cited by 159
Cheung, N. V., Guo, H.-F., Hu, J., Tassev, D. V., & Cheung, I. Y. (2012) · OncoImmunology · doi:10.4161/onci.19864 · Cited by 159
Jacobson, A. F., Deng, H., Lombard, J., Lessig, H. J., & Black, R. R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2604 · Cited by 157
Marshall, G. M., Liu, P. Y., Gherardi, S., Scarlett, C. J., Bedalov, A., Xu, N., Iraci, N., Valli, E., Ling, D., Thomas, W. D., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002135 · Cited by 153
The Role of Histone Acetyltransferases in Normal and Malignant Hematopoiesis
Sun, X., Man, N., Tan, Y., Nimer, S. D., & Wang, L. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00108 · Cited by 152
A Notch1 Ectodomain Construct Inhibits Endothelial Notch Signaling, Tumor Growth, and Angiogenesis
Funahashi, Y., Hernandez, S. L., Das, I., Ahn, A., Huang, J., Vorontchikhina, M., Sharma, A., Kanamaru, E., Borisenko, V., DeSilva, D. M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6499 · Cited by 151
Self-citationBeppu, K., Jaboine, J., Merchant, M., Mackall, C. L., & Thiele, C. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh004 · Cited by 149
Lanz, T. A., Himes, C. S., Pallante, G., Adams, L., Yamazaki, S., Amore, B., & Merchant, K. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.048280 · Cited by 148
MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death
Barbieri, E., Mehta, P. S., Chen, Z., Zhang, L., Slack, A., Berg, S. L., & Shohet, J. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0305 · Cited by 147
Sholler, G. L. S., Gerner, E. W., Bergendahl, G., MacArthur, R. B., VanderWerff, A., Ashikaga, T., Bond, J. P., Ferguson, W. S., Roberts, W. D., Wada, R. K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127246 · Cited by 145
Park, J. R., Scott, J. R., Stewart, C. F., London, W. B., Naranjo, A. H., Santana, V. M., Shaw, P. J., Cohn, S. L., & Matthay, K. K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3293 · Cited by 142
Henderson, T. O., Bhatia, R., Pinto, N. R., London, W. B., McGrady, P., Crotty, C., Sun, C., & Cohn, S. L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.6103 · Cited by 142
Gaze, M. N., Chang, Y.-C., Flux, G., Mairs, R. J., Saran, F. H., & Meller, S. T. (2005) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2005.20.195 · Cited by 141
The Phox2B homeobox gene is mutated in sporadic neuroblastomas
van Limpt, V., Schramm, A. R., Lakeman, A., Sluis, P. V., Chan, A., van Noesel, M. M., Baas, F., Caron, H. N., Eggert, A., & Versteeg, R. (2004) · Oncogene · doi:10.1038/sj.onc.1208157 · Cited by 140
Neuroblastoma (Peripheral neuroblastic tumours)
Luksch, R., Castellani, M. R., Collini, P., Bernardi, B. D., Conte, M., Gambini, C., Gandola, L., Garaventa, A., Biasoni, D., Podda, M. G., et al. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.10.001 · Cited by 140
Lasorella, A., Boldrini, R., Dominici, C., Donfrancesco, A., Yokota, Y., Inserra, A., & Iavarone, A. (2002) · PubMed · Cited by 139
Ham, J., Costa, C., Sano, R., Lochmann, T. L., Sennott, E. M., Patel, N. U., Dastur, A., Gomez‐Caraballo, M., Krytska, K., Hata, A. N., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.01.002 · Cited by 138
Stockhausen, M.-T., Sjölund, J., Manetopoulos, C., & Axelson, H. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602309 · Cited by 137
Bagatell, R., Popovic, M. B., London, W. B., Zhang, Y., Pearson, A. D. J., Matthay, K. K., Monclair, T. F., Ambros, P. F., & Cohn, S. L. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.9184 · Cited by 136
Holmes, K., Pötschger, U., Pearson, A. D. J., Sarnacki, S., Cecchetto, G., Gómez-Chacón, J., Squire, R., Freud, E., Bysiek, A., Matthyssens, L., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03117 · Cited by 136
Pietras, A., Hansford, L. M., Johnsson, A. S., Bridges, E., Sjölund, J., Gisselsson, D., Rehn, M., Beckman, S., Noguera, R., Navarro, S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904606106 · Cited by 135
Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome
Padovan-Merhar, O. M., Raman, P., Ostrovnaya, I., Kalletla, K., Rubnitz, K. R., Sanford, E. M., Ali, S. M., Miller, V. A., Mossé, Y. P., Granger, M. P., et al. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006501 · Cited by 135
11q deletion in neuroblastoma: a review of biological and clinical implications
Mlakar, V., Mlakar, S. J., López, G., Maris, J. M., Ansari, M., & Gumy‐Pause, F. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0686-8 · Cited by 134
Kushner, B. H., Cheung, I. Y., Modak, S. I., Basu, E. M., Roberts, S. S., & Cheung, N. V. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4005 · Cited by 132
Twist, C. J., Schmidt, M. L., Naranjo, A. H., London, W. B., Tenney, S. C., Marachelian, A., Shimada, H., Collins, M. H., Esiashvili, N., Adkins, E. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00919 · Cited by 131
Targets and Antibody Formats for Immunotherapy of Neuroblastoma
Park, J. A., & Cheung, N. V. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01410 · Cited by 129
Histone acetyltransferase inhibitors block neuroblastoma cell growth in vivo
Gajer, J. M., Furdas, S. D., Gründer, A., Gothwal, M., Heinicke, U., Keller, K., Colland, F., Fulda, S., Pahl, H. L., Fichtner, I., et al. (2015) · Oncogenesis · doi:10.1038/oncsis.2014.51 · Cited by 128
Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines
Dirks, W. G., Fähnrich, S., Lis, Y., Becker, E., MacLeod, R. A. F., & Drexler, H. G. (2002) · International Journal of Cancer · doi:10.1002/ijc.10435 · Cited by 125
Maerken, T. V., Ferdinande, L., Taildeman, J., Lambertz, I., Yigit, N., Vercruysse, L., Rihani, A., Michaelis, M., Cinatl, J. J., Cuvelier, C. A., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp355 · Cited by 125
Schönherr, C., Ruuth, K., Kamaraj, S., Wang, C.-L., Yang, H.-L., Combaret, V., Djos, A., Martinsson, T., Christensen, J. G., Palmer, R. H., et al. (2012) · Oncogene · doi:10.1038/onc.2012.12 · Cited by 122
Shahbazi, J., Liu, P. Y., Atmadibrata, B., Bradner, J. E., Marshall, G. M., Lock, R. B., & Liu, T. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1666 · Cited by 122
Neuroblastoma pathogenesis: deregulation of embryonic neural crest development
Tomolonis, J., Agarwal, S., & Shohet, J. M. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2747-0 · Cited by 122
Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma.
Corvi, R., Savelyeva, L., Breit, S., et al. (1995) · PubMed · Cited by 119
Accumulation of Cytosolic Calcium Induces Necroptotic Cell Death in Human Neuroblastoma
Nomura, M., Ueno, A., Saga, K., Fukuzawa, M., & Kaneda, Y. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1283 · Cited by 119
Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma
DuBois, S. G., & Matthay, K. K. (2008) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2008.05.002 · Cited by 117
Chandele, A., Prasad, V., Jagtap, J. C., Shukla, R., & Shastry, P. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80051-4 · Cited by 116
Miyake, I., Hakomori, Y., Shinohara, A., Gamou, T., Saito, M., Iwamatsu, A., & Sakai, R. (2002) · Oncogene · doi:10.1038/sj.onc.1205735 · Cited by 116
Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe
Lamers, F., van der Ploeg, I., Schild, L. G., Ebus, M. E., Köster, J., Hansen, B. R., Koch, T., Versteeg, R., Caron, H. N., & Molenaar, J. J. (2011) · Endocrine Related Cancer · doi:10.1530/erc-11-0207 · Cited by 113
A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis
Schnepp, R. W., Khurana, P., Attiyeh, E. F., Raman, P., Chodosh, S., Oldridge, D. A., Gagliardi, M. E., Conkrite, K. L., Asgharzadeh, S., Seeger, R. C., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.012 · Cited by 112
Deregulated Wnt/β-catenin program in high-risk neuroblastomas without MYCN amplification
Liu, X., Mazánek, P., Dam, V., Wang, Q., Zhao, H., Guo, R. J., Jagannathan, J., Cnaan, A., Maris, J. M., & Hogarty, M. D. (2007) · Oncogene · doi:10.1038/sj.onc.1210769 · Cited by 109
The neurotrophic receptor TrkB: a drug target in anti-cancer therapy?
Desmet, C. J., & Peeper, D. S. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5490-8 · Cited by 106
Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma
Meister, B., Grünebach, F., Bautz, F., Brugger, W., Fink, F. M., Kanz, L., & Möhle, R. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00387-6 · Cited by 101
Coughlan, D., Gianferante, M., Lynch, C. F., Stevens, J. L., & Harlan, L. C. (2017) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2017.1373315 · Cited by 101
Eggert, A., Grotzer, M. A., Ikegaki, N., Liu, X. G., Evans, A. E., & Brodeur, G. M. (2002) · PubMed · Cited by 100
MDM2 Regulates Vascular Endothelial Growth Factor mRNA Stabilization in Hypoxia
Zhou, S., Gu, L., He, J., Zhang, H., & Zhou, M. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.06085-11 · Cited by 100
Expression and function of TRK-B and BDNF in human neuroblastomas
Nakagawara, A., Azar, C. G., Scavarda, N. J., & Brodeur, G. M. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.1.759-767.1994 · Cited by 100
Yanik, G. A., Villablanca, J. G., Maris, J. M., Weiss, B., Groshen, S. G., Marachelian, A., Park, J. R., Tsao-Wei, D. D., Hawkins, R. A., Shulkin, B. L., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.12.008 · Cited by 99
The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma
Azuhata, T., Scott, D., Takamizawa, S., Wen, J., Davidoff, A. M., Fukuzawa, M., & Sandler, A. D. (2001) · Journal of Pediatric Surgery · doi:10.1053/jpsu.2001.28839 · Cited by 98
Goldman, S. C., CHEN, C.-Y., Lansing, T. J., Gilmer, T. M., & Kastan, M. (1996) · Europe PMC (PubMed Central) · Cited by 97
Targeting of the MYCN Protein with Small Molecule c-MYC Inhibitors
Müller, I., Larsson, K., Frenzel, A., Oliynyk, G., Zirath, H., Prochownik, E. V., Westwood, N. J., & Arsenian‐Henriksson, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097285 · Cited by 97
Genetic predisposition and chromosome instability in neuroblastoma
Tonini, G. P., & Capasso, M. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09843-4 · Cited by 97
Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model
Iyer, R., Wehrmann, L., Golden, R., Naraparaju, K., Courtland, J. L., MacFarland, S. P., Guan, P. F., Kolla, V., Ge, W., Cam, N. R., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.018 · Cited by 93
Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment
Titov, A., Valiullina, A., Zmievskaya, E., Zaikova, E. K., Petukhov, A., Рифкатовна, М. Р., Bulatov, E., & Rizvanov, A. A. (2020) · Cancers · doi:10.3390/cancers12010125 · Cited by 93
DuBois, S. G., Mossé, Y. P., Fox, E., Kudgus, R. A., Reid, J. M., McGovern, R. M., Groshen, S. G., Bagatell, R., Maris, J. M., Twist, C. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1381 · Cited by 90
Genetic Predisposition to Neuroblastoma
Barr, E. K., & Applebaum, M. A. (2018) · Children · doi:10.3390/children5090119 · Cited by 90
Rocchi, P., Tonelli, R., Camerin, C., Purgato, S., Fronza, R., Bianucci, F., Guerra, F., Pession, A., & Ferreri, A. M. (2005) · Oncology Reports · doi:10.3892/or.13.6.1139 · Cited by 89
MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63
Gamble, L. D., Kees, U. R., Tweddle, D. A., & Lunec, J. (2011) · Oncogene · doi:10.1038/onc.2011.270 · Cited by 87
Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression
Evageliou, N. F., Haber, M., Vu, A. T., Laetsch, T. W., Murray, J. E., Gamble, L. D., Cheng, N. C., Liu, K., Reese, M., Corrigan, K. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2539 · Cited by 87
Ozkaynak, M. F., Gilman, A. L., London, W. B., Naranjo, A. H., Diccianni, M. B., Tenney, S. C., Smith, M. A., Messer, K. S., Seeger, R. C., Reynolds, C. P., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01355 · Cited by 87
Autophagy Control by the VEGF-C/NRP-2 Axis in Cancer and Its Implication for Treatment Resistance
Stanton, M. J., Dutta, S., Zhang, H., Polavaram, N. S., Leontovich, A. A., Hönscheid, P., Sinicrope, F. A., Tindall, D. J., Muders, M. H., & Datta, K. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3635 · Cited by 86
Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma
Hart, L. S., Rader, J., Raman, P., Batra, V., Russell, M. R., Tsang, M., Gagliardi, M. E., Chen, L. L., Martínez, D., Li, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1131 · Cited by 86
BIRC5/Survivin as a target for glycolysis inhibition in high-stage neuroblastoma
Hagenbuchner, J., Kiechl‐Kohlendorfer, U., Obexer, P., & Ausserlechner, M. J. (2015) · Oncogene · doi:10.1038/onc.2015.264 · Cited by 85
Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts.
Evans, A. E., Kisselbach, K. D., Yamashiro, D. J., Ikegaki, N., Camoratto, A. M., Dionne, C. A., & Brodeur, G. M. (1999) · PubMed · Cited by 85
Molecular mechanisms and therapeutic targets in neuroblastoma
Johnsen, J. I., Dyberg, C. H., Fransson, S. M., & Wickström, M. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.023 · Cited by 84
Santos, M. D. L., Zambrano, A., & Aranda, A. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0623 · Cited by 83
Current management of neuroblastoma and future direction
Pastor, E. R., & Mousa, S. A. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.03.013 · Cited by 83
Mastrangelo, S., Tornesello, A., Diociaiuti, L., Pession, A., Prete, A., Rufini, V., Troncone, L., & Mastrangelo, R. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1645 · Cited by 80
Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis
Bellini, A., Bernard, V., Leroy, Q., Frio, T. R., Pierron, G., Combaret, V., Lapouble, E., Clément, N., Rubie, H., Thébaud, E., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0423 · Cited by 78
Lakoma, A., Barbieri, E., Agarwal, S., Jackson, J. R., Chen, Z., Kim, Y., McVay, M. C., Shohet, J. M., & Kim, E. S. (2015) · Cell Death Discovery · doi:10.1038/cddiscovery.2015.26 · Cited by 78
MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells
Gu, L., Zhang, H., He, J., Li, J., Huang, M. J., & Zhou, M. (2011) · Oncogene · doi:10.1038/onc.2011.343 · Cited by 77
Targeting of HDAC8 and investigational inhibitors in neuroblastoma
Oehme, I., Deubzer, H. E., Lodrini, M., Milde, T., & Witt, O. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/14728220903241658 · Cited by 77
Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma
Voeller, J., & Sondel, P. M. (2018) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001369 · Cited by 77
Revet, I. M., Huizenga, G., Chan, A., Köster, J., Volckmann, R., Sluis, P. V., Øra, I., Versteeg, R., & Geerts, D. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.12.008 · Cited by 75
Genetic susceptibility to neuroblastoma: current knowledge and future directions
Egolf, L. E., Randall, M. P., Bosse, K. R., & Diskin, S. J. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2820-3 · Cited by 75
Puppo, M., Battaglia, F., Ottaviano, C., Delfino, S., Ribatti, D., Varesio, L., & Bosco, M. C. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2059 · Cited by 74
Boller, D., Schramm, A. R., Doepfner, K. T., Shalaby, T., von Bueren, A. O., Eggert, A., Grotzer, M. A., & Arcaro, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0737 · Cited by 74
Cheung, I. Y., Hsu, K. C., & Cheung, N. V. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.6236 · Cited by 72
Schultze, K., Böck, B. C., Eckert, A., Oevermann, L., Ramacher, D., Wiestler, O. D., & Roth, W. (2006) · APOPTOSIS · doi:10.1007/s10495-006-8896-3 · Cited by 72
Simon, T., Längler, A., Harnischmacher, U., Frühwald, M. C., Jorch, N., Claviez, A., Berthold, F., & Hero, B. (2007) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0216-y · Cited by 69
Parisi, M. T., Khalatbari, H. K., Park, J. R., Shulkin, B. L., & Yanik, G. A. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.02.002 · Cited by 69
Lamers, F., Schild, L. G., Köster, J., Versteeg, R., Caron, H. N., & Molenaar, J. J. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.012 · Cited by 68
Cantilena, S., Pastorino, F., Pezzolo, A., Chayka, O., Pistoia, V., Ponzoni, M., & Sala, A. (2011) · Oncotarget · doi:10.18632/oncotarget.410 · Cited by 68
Notch signaling in neuroblastoma
Påhlman, S., Stockhausen, M., Fredlund, E., & Axelson, H. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.04.016 · Cited by 67
Cazes, A., Louis‐Brennetot, C., Mazot, P., Dingli, F., Lombard, B., Boeva, V., Daveau, R., Cappo, J., Combaret, V., Schleiermacher, G., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1242 · Cited by 67
Metadata
- Authors
- Zafar, A., Wang, W., Liu, G., Wang, X., Xian, W., McKeon, F., Foster, J., Zhou, J., & Zhang, R.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2020-11-06
- Volume
- 41
- Issue
- 2
- Pages
- 961-1021
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W3095538345
- Cited by
- 380
- References
- 291
- FWCI
- 15.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.